PREOPANC-2 试验:新辅助治疗后胰腺切除手术并发症分析
PREOPANC-2 随机试验预设分析比较可切除或交界可切除胰腺癌患者接受新辅助 FOLFIRINOX 或吉西他滨为基础放化疗后手术并发症。375 例随机分组,280 例(74.7%)接受胰腺切除。两组主要手术并发症发生率相似(26.8% vs 27.5%,P=0.884),90 天死亡率低(1.4% vs 2.9%,P=0.442)。
要点
- 新辅助 FOLFIRINOX 与吉西他滨放化疗后胰腺切除主要并发症发生率无差异。
- 两组术后胰瘘 B/C 级、切除后出血 B/C 级、胆漏 B/C 级及再次手术率均无统计学差异。
- 术后 90 天死亡率低,FFX 组 1.4%,CRT 组 2.9%。
核心结论
- 新辅助 FOLFIRINOX 或吉西他滨为基础放化疗后行胰腺切除,主要手术并发症风险相似,总体 90 天死亡率低。
研究设计与样本
- 研究为研究者发起的全国性随机对照 PREOPANC-2 试验的预设分析。
- 2018 年 6 月 5 日至 2021 年 1 月 28 日共随机 375 例可切除或交界可切除胰腺癌患者,280 例(74.7%)接受胰腺切除。
- 280 例手术患者中,胰十二指肠切除术 238 例(85.0%),左胰腺切除 41 例(14.6%),全胰腺切除 1 例(0.4%)。
主要发现
- FFX 组与 CRT 组主要手术并发症(Clavien-Dindo ≥3 级)发生率分别为 26.8% 与 27.5%(P=0.884)。
- 术后胰瘘 B/C 级发生率 FFX 组 9.9%、CRT 组 4.4%(P=0.076)。
- 切除后出血 B/C 级发生率 FFX 组 7.7%、CRT 组 3.6%(P=0.137)。
- 胆漏 B/C 级发生率两组均为 2.5%(P>0.999),术后干预率分别为 26.1% 与 26.8%(P=0.886)。
- 再次手术率 FFX 组 6.3%(9 例)、CRT 组 5.8%(8 例)(P=0.850);90 天死亡率 FFX 组 1.4%(2/142)、CRT 组 2.9%(4/138)(P=0.442)。
临床怎么用
- 新辅助 FOLFIRINOX 或吉西他滨放化疗后行胰腺切除时,主要手术并发症风险相似,围术期管理可参照同类标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the incidence of major surgical complications between patients with (borderline) resectable pancreatic cancer treated with neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy. SUMMARY OF BACKGROUND DATA: There are ongoing concerns regarding the possible adverse impact of neoadjuvant treatment on postoperative complication rates following pancreatectomy. METHODS: This study was a predefined analysis within the investigator-initiated nationwide randomized controlled PREOPANC-2 trial. Patients with (borderline) resectable pancreatic cancer were randomized to receive neoadjuvant FOLFIRINOX (FFX group) or neoadjuvant gemcitabine-based chemoradiotherapy (CRT group), both followed by surgery, and adjuvant gemcitabine only in the CRT group. Surgical complications including postoperative pancreatic fistula, postpancreatectomy hemorrhage, bile leakage, postoperative interventions, and 90-day mortality were compared, with major complications defined as Clavien-Dindo grade ≥3. RESULTS: Between June 5, 2018, and January 28, 2021, in total 375 patients were randomized, of whom 280 (74.7%) underwent pancreatic resection. A pancreatoduodenectomy was performed in 238 patients (85.0%), left pancreatectomy in 41 patients (14.6%), and total pancreatectomy in one patient (0.4%). The incidence of major surgical complications was similar between the FFX and CRT groups (26.8% versus 27.5%, P=0.884). No differences were observed in the risk of postoperative pancreatic fistula grade B/C (9.9% versus 4.4%, P=0.076), postpancreatectomy hemorrhage grade B/C (7.7% versus 3.6%, P=0.137), bile leakage grade B/C (2.5% versus 2.5%, P>0.999), and postoperative interventions (26.1% versus 26.8%, P=0.886). Surgical reoperation was performed in nine patients (6.3%) in the FFX group and eight patients (5.8%) in the CRT group (P=0.850). The postoperative 90-day mortality was 1.4% in the FFX group (2/142 patients) and 2.9% in the CRT group (4/138 patients) (P=0.442). CONCLUSIONS: In the PREOPANC-2 randomized trial, the risk of major surgical complications after pancreatic resection following neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine-based chemoradiotherapy was similar with an overall low 90-day mortality.
引用
- Dekker EN, Theijse RT, van Dam JL, et al. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Ann Surg. 2025. PMID: 40792645. doi:10.1097/SLA.0000000000006910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。